MedPath

Novo Nordisk A/S

Novo Nordisk A/S logo
🇩🇰Denmark
Ownership
Public
Established
1923-01-01
Employees
63.3K
Market Cap
$602.2B
Website
http://www.novonordisk.com

Prevalence and Economic Burden of Obesity-related Comorbidities in the Gulf Region: A Retrospective, Observational Study

Completed
Conditions
Obesity
Interventions
Other: No treatment given
First Posted Date
2024-03-01
Last Posted Date
2024-10-18
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
1322
Registration Number
NCT06288399
Locations
🇰🇼

Farwaniya Hospital, Farwaniya, Kuwait

🇰🇼

Al-Adan Hospital, Hadiya, Kuwait

🇰🇼

Al-Amiri Hospital, Kuwait City, Kuwait

and more 4 locations

A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting

Phase 1
Recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2024-03-01
Last Posted Date
2024-04-02
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
30
Registration Number
NCT06288412
Locations
🇦🇹

Medical University of Graz, Graz, Austria

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Conditions
Haemophilia B
Haemophilia A
Interventions
First Posted Date
2024-02-29
Last Posted Date
2024-08-21
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
23
Registration Number
NCT06285071
Locations
🇯🇵

Mutsu general hospital, Aomori, Japan

🇯🇵

Novo Nordisk Investigational Site, Toshima, Tokyo, Japan

🇯🇵

Sapporo Tokushukai Hospital_Pediatrics, Hokkaido, Japan

and more 1 locations

A Research Study of a New Medicine (NNC0650-0013) in Healthy Men

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: NNC0650-0013 A
Drug: Placebo
First Posted Date
2024-02-29
Last Posted Date
2024-11-19
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
11
Registration Number
NCT06284798
Locations
🇩🇪

Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Special Use - Results Surveillance on Long-term Use With Wegovy®

Conditions
Obesity
Interventions
First Posted Date
2024-02-28
Last Posted Date
2024-12-12
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
1000
Registration Number
NCT06283667
Locations
🇯🇵

Osaki citizen hospital, Diabetes and metabolic disease, Osaki-shi, Miyagi, Japan

🇯🇵

Novo Nordisk Investigational Site, Tokyo, Chiyoda City, Japan

🇯🇵

Okazaki City Hospital, Aichi, Japan

and more 29 locations

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Active, not recruiting
Conditions
Obesity
Interventions
First Posted Date
2024-02-28
Last Posted Date
2024-12-12
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
288
Registration Number
NCT06283641
Locations
🇨🇳

Changhua Christian Hospital, Changhua City, Taiwan

🇨🇳

HsinChu Municipal MacKay Children's Hospital, Hsinchu City, Taiwan

🇨🇳

HsinChu MacKay Memorial Hospital, Hsinchu City, Taiwan

and more 11 locations

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

Not yet recruiting
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2024-02-21
Last Posted Date
2024-02-21
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
470
Registration Number
NCT06269120

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

Phase 3
Active, not recruiting
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2024-02-21
Last Posted Date
2024-11-19
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
474
Registration Number
NCT06269107
Locations
🇺🇸

Consano Clinical Research, LLC, Shavano Park, Texas, United States

🇺🇸

TPMG Clinical Research, Newport News, Virginia, United States

🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

and more 89 locations

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Phase 1
Active, not recruiting
Conditions
Overweight
Obesity
Interventions
Other: No treatment given
Drug: Cagrilintide and Semaglutide
Drug: Placebo
First Posted Date
2024-02-20
Last Posted Date
2024-12-11
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
150
Registration Number
NCT06267092
Locations
🇩🇪

Charité Research Organisation GmbH, Berlin, Germany

Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by Gender

Completed
Conditions
Overweight
Obesity
Interventions
Other: No treatment is given
First Posted Date
2024-02-15
Last Posted Date
2024-02-15
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
3000
Registration Number
NCT06260696
Locations
🇦🇪

Novo Nordisk Investigational Site, Dubai, United Arab Emirates

© Copyright 2025. All Rights Reserved by MedPath